Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Vaxcyte (PCVX) Assets Average (2020 - 2026)

Vaxcyte (PCVX) has 7 years of Assets Average data on record, last reported at $3.2 billion in Q1 2026.

  • On a quarterly basis, Assets Average fell 7.81% to $3.2 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $3.2 billion, a 7.81% decrease, with the full-year FY2025 number at $3.3 billion, up 32.42% from a year prior.
  • Assets Average reached $3.2 billion in Q1 2026 per PCVX's latest filing, up from $3.1 billion in the prior quarter.
  • Over the last five years, Assets Average for PCVX hit a ceiling of $3.5 billion in Q4 2024 and a floor of $363.5 million in Q1 2022.
  • A 5-year average of $2.0 billion and a median of $1.7 billion in 2024 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: surged 264.08% in 2023, then dropped 12.68% in 2025.
  • Tracing PCVX's Assets Average over 5 years: stood at $709.1 million in 2022, then skyrocketed by 104.76% to $1.5 billion in 2023, then surged by 143.5% to $3.5 billion in 2024, then decreased by 12.68% to $3.1 billion in 2025, then rose by 2.86% to $3.2 billion in 2026.
  • Business Quant data shows Assets Average for PCVX at $3.2 billion in Q1 2026, $3.1 billion in Q4 2025, and $3.2 billion in Q3 2025.